TIA congratulates the six recipients of the first round of the MedChem Australia application. Established in 2023, MedChem Australia is committed to helping translate innovative biomedical research into new medicines and commercial opportunities by connecting outstanding Australian science with medicinal chemistry and drug metabolism and pharmacokinetics (DMPK) expertise. Headquartered at the Monash Institute of Pharmaceutical Sciences in Parkville, MedChem Australia is a partnership between Monash University, WEHI, University of Sydney and Therapeutic Innovation Australia, with support from the Australian federal government’s Medical Research Future Fund.
Applications were received from universities and research institutes from four states, addressing unmet needs across eight different therapeutic areas. Following assessment by the independent Selection and Review Committee, six projects were selected, three as ‘Portfolio Projects’ and three as ‘Pilot Projects’.
MedChem Australia Portfolio Projects will be backed by game-changing support in medicinal chemistry and DMPK at an 80 per cent subsidy. Pilot Projects will receive mentorship, advice and other support, with the aim to progress toward being ‘Portfolio Project’ ready.
The selected projects all seek to develop new therapeutic interventions for different cancers, heart disease, a paediatric genetic disorder, hearing loss, and obesity.
For more information on the awarded projects, click below.
MedChem Australia is a terrific example of complementary therapeutic development expertise coming together with a common goal, and an example of how we can better tap the potential of Australia's outstanding medical research and translate it into meaningful impacts.
